Compare Bristol-Myers Squibb Co (BMY) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X SuperDividend ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $132.45B), while Global X SuperDividend ETF trades at $24.56. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Global X SuperDividend ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SDIV | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $26.34 |
52-Week Low | $42.60 | $22.90 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SDIV trades at $24.81, up 1.02% with a neutral technical signal. The ETF maintains a consistent dividend payout of $0.18 monthly, providing a high yield for income-focused investors. Recent news highlights SDIV's role in diversification away from AI-heavy portfolios, with Seeking Alpha upgrading it to a buy rating citing attractive valuation and 9.29% yield. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
SDIV offers exposure to global high-dividend stocks with minimal tech exposure, appealing during market volatility. Key risks include concentration in financials and energy sectors, interest rate sensitivity, and geopolitical factors affecting dividend sustainability. The fund's 6% yield target provides income stability but requires monitoring of underlying holdings' financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
